Publications by authors named "Ling-Yu Long"
Article Synopsis
- High expression of WT1 at diagnosis in acute myeloid leukemia (AML) patients is linked to lower rates of complete remission after treatment, particularly in specific genetic subgroups.
- In a study with 437 adult AML patients, 92.4% showed WT1 overexpression, which is associated with certain mutations like FLT3-ITD and NPM1.
- Subgroup analyses indicate that high WT1 levels are a significant negative prognostic factor, affecting CR rates without impacting relapse-free survival in many cases, underscoring the need for tailored treatment strategies.
More clinical studies are needed to clarify the risk stratification by the integration of all fusion genes in adult B-cell precursor acute lymphoblastic leukemia (BCP-ALL). A total of 320 consecutive adult Ph-negative BCP-ALL patients who had been tested classical fusions (KMT2A rearrangement and TCF3-PBX1) at diagnosis were further retrospectively screened novel fusion genes (Ph-like, ZNF384 and MEF2D fusions) by multiplex real-time quantitative PCR (RQ-PCR). Classical fusions were identified in 12.
View Article and Find Full Text PDFArticle Synopsis
- High levels of EVI1 expression are known to be a bad sign for acute myeloid leukemia, but its effects in pediatric BCP-ALL are not well studied.
- A study of 176 pediatric Ph-negative BCP-ALL patients revealed that lower EVI1 levels at diagnosis (specifically <0.10%) are linked to significantly worse 5-year relapse-free survival and overall survival rates.
- Multivariate analysis confirmed that low EVI1 expression is an independent factor predicting poor outcomes for these patients, with additional data supporting a similar trend in overall survival rates.
Acute myeloid leukemia with intermediate cytogenetic risk (ICR-AML) needs to be stratified and abnormal gene expression might be prognostic. PR/SET domain 16 () transcript levels were assessed in 267 consecutive adult ICR-AML patients at diagnosis by real-time quantitative PCR. 38.
View Article and Find Full Text PDFPurpose: The cancer-testis antigen, which is a preferentially expressed antigen of melanoma (PRAME), is an ideal target for immunotherapy and cancer vaccines. Since the expression of this antigen is relevant to therapy responses, the heterogeneity in its expression and the underlying mechanism need to be investigated.
Patients And Methods: Plasma cell sorting was performed in 48 newly diagnosed multiple myeloma (MM) patients.
Multiple myeloma (MM) patients commonly present abnormal expression of cancer-testis antigens, which may serve as immunotherapeutic targets and prognostic factors. We previously reported that preferentially expressed antigen of melanoma (PRAME) overexpression in bone marrow mononuclear cells is related to progression in MM patients treated with non-bortezomib-containing regimens. The mechanism underlying variations in PRAME expression remains unknown.
View Article and Find Full Text PDFTo investigate the prognostic value of PRAME expression in pediatric acute lymphoblastic leukemia(ALL), we measured PRAME transcript levels at diagnosis in 191 patients(146 B-ALL; 45T-ALL)receiving chemotherapy only. PRAME overexpression was defined as transcript levels higher than 0.30%, which is the upper limit of normal bone marrow and the optimal cutoff value derived from ROC curve analysis.
View Article and Find Full Text PDF